<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Aug. 5, 2020 (HealthDay News) — Maryland-based Novavax said Tuesday that preliminary trials of an experimental COVID-19 vaccine were promising.<\/p>\n
In one study, 56 people made high levels of antibodies against COVID-19 with no adverse side effects. In a second study, the vaccine protected monkeys from COVID-19 infection.<\/p>\n
It is not possible to compare the data from clinical trials of different vaccines, but John Moore, Ph.D., a virologist at Weill Cornell Medicine who was not involved in the studies, told The New York Times<\/i> that these results were the most impressive he had seen and added that “this is the first one I’m looking at and saying, ‘Yeah, I’d take that.'”<\/p>\n
In its 33-year history, Novavax has never had a vaccine on the market, but it has received $1.6 billion in federal funding for vaccine development. If the vaccine is effective, the company said it can make 100 million doses by the beginning of 2021 — enough to inoculate 50 million people with the required two doses.<\/p>\n